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1. Introduction
Brain tumors are a large and heterogeneous group of neoplasms affecting the central nervous
system that, despite the progress of the modern medicine, still represent a great challenge for
physicians all over the world. The annual global age-standardized incidence of primary
malignant brain tumors is ~3.7 per 100,000 for males and 2.6 per 100,000 for females. Rates
appear to be higher in more developed countries (males 5.8, and females 4.1 per 100,000) than
in less developed countries (males 3.0 and females 2.1 per 100,000). Conversely, the incidence
of both primary malignant and non-malignant brain tumors is about 10 - 14 cases per 100,000/
year all over the world, with white males having the highest rate. Males also generally have
higher rates of primary malignant brain tumors while females have higher rates of non-
malignant tumors, primarily meningiomas. Worldwide age-standardized mortality for
primary malignant brain tumors is ~2.8 for male and 2.0 for females per 100,000. Mortality
rates differ significantly by histology and age. For example, glioblastoma multiforme (GBM)
has a 5-year survival rate of 3.3%, low grade gliomas, such as pilocytic astrocytomas, oligo‐
dendrogliomas, and ependymomas have 5-year survival rates of over 70%, while anaplastic
astrocytoma, malignant gliomas and lymphomas have 5-year survival rates less than 40% [1].
Due to these dramatic epidemiological data, in the past decades we assisted to the birth of an in‐
tensifying interest in understanding the causes of brain tumors among the scientific communi‐
ty.  Despite  notable  advances  achieved during recent  years  in  both surgical  and chemo/
radiotherapeutic approaches, an improved survival has not been clearly documented, especial‐
ly for primary malignant brain tumors. This is partially due to the tumors’ intrinsic clinical and
molecular heterogeneity. As a matter of fact, choice of initial treatment, prediction of survival,
stratification of patients, prediction and monitoring of response to therapy, still represent some
© 2013 La Torre et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
of the greatest challenges in the management of patients affected by brain tumors. In these set‐
tings, different studies have been performed to better understand the pathophysiology of cere‐
bral neoplasms, with the aim to identify new molecular prognostic markers and therapeutic
targets. However, until now, molecular biomarkers that effectively predict response to therapy
and/or survival outcomes in brain tumors are limited. Consequently, there is a strong need to
develop novel and independent markers of prognosis for these neoplasms. One of the cellular
structure candidate to accomplish this role is represented by telomeres.
Telomeres consist of long tandem arrays of TTAGGG repeats, bound by proteins, placed at
the end of linear chromosomes, which are involved in several essential biological functions [2,
3]. These non-coding telomeric repeats represent a buffer zone preventing the adjacent coding
region of the genome from erosion. In normal human cells, the telomeres decreases by some
5-20 repeats with every cell division [4]. Therefore telomere shortening limits the number of
times a cell can divide.[5] Hence, they can be considered the mitotic clock by which cells count
their divisions and regulate the onset of replicative senescence in somatic cells [6-8]. The
alteration of telomere length homeostasis affects telomere structure and leads to genomic
instability by generating chromosome end-to end fusion and chromosomal abnormalities [9].
It has been demonstrated that telomeres shortening could initiate successive events, such as
aberrant fusions or recombination of the end of chromosomes, genomic instability, loss of cell
growth control, and finally cancer development [10, 11]. Hence, cells exhibiting critical
telomeres shortening and genomic instability present an increased capacity of dicentric
chromosomes formation and susceptibility to oncogenic transformation [5, 12, 13]. Several
studies showed the presence of an hypervariability of telomere length in different human solid
tumors, including brain tumors, suggesting for telomeres and proteins involved in the
modulation of their length a possible clinical role as diagnostic/prognostic marker or thera‐
peutic target for cancer treatment.
2. Telomeres
Human telomeres are regions of 4-15 kilobases of repetitive hexameric (TTAGGG)n guanine-
rich DNA sequences at the ends of each chromosome [14]. They end with a single-stranded 3'-
overhang that folds back and invades its complementary strand to form a T-loop [15].
Formation of this structure is presumed to involve the insertion of the 3’-telomeric overhang
into duplex telomeric DNA, its hybridization with the cytosine-rich strand, and dislodgment
of the guanine-rich strand into a displacement loop (D-loop) [16]. It has been demonstrated
that T-loops are especially well-adapted to shield the ends of chromosomes from DNA repair
and DNA damage-sensing mechanisms [15, 17]. Moreover, a complex of telomere-specific
proteins, named shelterin complex, binds and caps telomeres, further preventing chromoso‐
mal ends from being recognized as DNA double strand breaks (DSB) by the DNA damage
response (DDR) machinery [18, 19]. As the lagging strands of telomeres are incapable of being
fully replicated during each round of cell division, telomeres undergo progressive shortening
during normal cellular proliferation. Eventually, they become so short that they trigger the
DDR, causing cell crisis [4, 18, 20]. This normally results in replicative senescence and even‐
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tually checkpoint-driven cell death and apoptosis, defining cellular lifespan and safeguarding
an organism against unlimited cellular proliferation and cancer [19, 21, 22].
Shelterin complex proteins interact selectively with telomeric DNA and localize to telomeres.
In its most abundant form, the complex is composed of six core components: TRF1, TRF2,
POT1, TIN2, TPP1 and RAP1[16]. TRF1 and TRF2 (Telomeric Repeat Factors 1 and 2) recognize
duplex telomeric DNA whereas POT1 (Protection of Telomere 1) associates with the single-
strand telomeric DNA present at the 3′-overhang [23, 24]. The scaffolding subunit TIN2 (TRF1-
interacting nuclear protein 2) binds simultaneously to TRF1, TRF2 and TPP1, whereas TPP1
(previously known as TINT 1 [25] ) connects POT1 with TIN2 [25-31]. A sixth component,
RAP1 (Repressor Activator Protein 1), is a TRF2-associated factor [32]. Via protein–protein
interactions, these DNA binding factors bring a number of other proteins to telomeres, where
they localize to form a variety of complexes [33, 34], playing a key role in telomere capping
and length regulation (see Figure 1).
 
Figure 1. Schematic representation of the six subunits of the Shelterin complex on the telomeric DNA and of their
molecular structure, including domains, protein interactions and DNA binding sites.
In addition to this 6-member complex, Shelterin may also be present in the form of sub-
complexes that lack either TRF1 or TRF2/RAP1[30, 34-41]. While the importance of these
different sub-complexes remains unclear, the particular function of each of the three DNA
binding subunits (TRF1, TRF2 and POT1) is well-understood.
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TRF1 has a key role in the modulation of telomere length. Its ADP-ribosylation, allow telo‐
merase to bind telomeres and start their elongation.
TRF2 serves to block recognition of telomeres as double-strand DNA breaks. Loss of TRF2
function leads to the activation of the ATM kinase (Ataxia telangiectasia mutated kinase),
formation of telomere dysfunction-induced foci (TIFs), and induction of either senescence or
apoptosis [21, 36, 42-45]. Moreover, in cells lacking functional checkpoints, telomeres devoid
of TRF2 serve as substrates for the NHEJ (non-homologous end-joining) repair mechanism
and give rise to interchromosomal fusions [41, 46]. TRF2 also appears to protect telomeres, at
least in part, through its ability to promote T-loop formation and maintenance [15, 17].
POT1 serves to hide the 3′-telomeric overhang from telomerase and from DNA damage
sensing mechanisms. Hence, the loss of POT1 leads to the activation of the ATR kinase (ATM
and Rad3-related kinase), formation of TIFs, and induction of either apoptosis or cell cycle
arrest [38, 42, 47, 48]. In cells that lack functional checkpoints, POT1 dysfunction leads to a loss
of telomerase regulation that results in longer telomeres [31, 39].
Therefore, through the interaction with the shelterin complex proteins, telomeres protect
chromosomes from recombination, end-to-end fusion, and recognition as damaged DNA,
providing a means for complete replication of chromosomes.
In summary, telomeres serve as a molecular clock that controls the replicative capacity of hu‐
man cells and their entry into senescence, but they also contribute to the functional organization
of chromosomes within the nucleus and participate in the regulation of gene expression [49, 50].
2.1. Telomere length modulation
During a process of DNA synthesis and cell division, telomeres shorten as a result of the
incomplete replication of linear chromosomes. This progressive shortening represent the so-
called ‘end-replication problem’.
As previously described, in order to prevent degradation by exonucleases or processing as
damaged DNA, the telomere 3’ single-strand overhang folds back into the D-loop of duplex
telomeric DNA to form a protective ‘T-loop’, which is reinforced with TRF2 and other telomeric
DNA-binding proteins that constitute the shelterin complex [51]. These proteins have a
fundamental role in the modulation of telomere length, allowing telomeres elongation or
conversely promoting their attrition.
In human cells, several pathways regulating telomeres length have been identified.
The most important mechanism is represented by telomerase, a highly specialized ribonuclear
reverse transcriptase enzyme that catalyzes extension of 5’-ends of the lagging DNA strand
by adding TTAGGG repeats onto the telomeres using its intrinsic RNA as a template for reverse
transcription [52]. Two major subunits of the human telomerase core complex have been
identified, named h-TERC and h-TERT. The former serves as a template for telomeres
elongation; instead, the latter subunit (h-TERT) contains a reverse transcriptase domain that
catalyzes this reaction [53] (see Figure 2).
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Figure 2. Schematic representation of telomere elongation by telomerase
However, the length and structure of telomeres are also controlled by a variety of proteins,
working exclusively at the telomere or contemporarily participating in DNA repair process.
Collectively, these telomeric proteins may function to protect telomere integrity and function,
to connect the DNA damage/repair network with the controls of cellular senescence, to monitor
telomere homeostasis and modify the access of telomerase to telomeres. Two major proteins
are the TRF1 and TRF 2 that are localized at telomeres [54]. These proteins play key roles in
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the maintenance of telomere function and structure modifying telomerase activity [41, 55, 56].
Moreover, a recent evidence shows that TRF1 interacts with other telomere-binding molecules
and is integrated into the functional telomere structure [57]. TRF1 accepts adenosine diphos‐
phate (ADP)-ribosylation catalyzed by the tankyrase-poli-ADP-ribose polymerase (TANKs-
PARP) complex. The ADP-ribosylation of TRF1 reduces its ability to bind telomeric DNA,
allowing telomerase to elongate telomeres and extending the cellular life span [58-60].
In most somatic cells telomerase is produced at very low levels. In contrast, many malignant
cells are able to upregulate this enzyme and extend their survival through continuous
telomeric elongation [61].
The vast majority of tumor cells use telomerase as preferred mechanism for telomere mainte‐
nance, whereas only 10-15% of all cancer lose the functional activity of telomerase and use the
telomerase-independent Alternative Lengthening of Telomeres pathway (ALT) that operates
via DNA repair and recombination processes [22].
ALT was first deduced in human cell lines from the fact that some telomerase-deficient lines
were able to be maintained in culture for many hundreds of population doubling times [62].
Later phenotypic studies revealed that, unlike telomerase-positive cells, ALT-dependent cells
almost always contain heterogeneous telomere length distribution and form ALT-associated
promyelocytic leukemia (PML) bodies or APBs. [63, 64] These phenotypes are either unde‐
tectable or have very low levels of activity in normal somatic cells. [22]
Several characteristic features are associated with ALT activity [65]. First, telomere length
distribution is highly heterogeneous and ranges from less than 3 kb to more than 50 kb [66].
In contrast, in human telomerase-positive cells all telomeres typically have a similar length of
around 10 kb. Second, ALT-positive cells have been described to contain several classes of
extrachromosomal telomeric repeats (ECTRs) in the nucleus. ECTRs comprise double- and
single-stranded circular molecules, linear telomeric DNA, and t-complex molecules that
consist of high molecular weight DNA with highly branched structures [67-70]. These DNA
fragments might be products of t-loop resolution by recombination enzymes. The function of
ECTRs in the telomere lengthening process is unknown but the amount of partially single-
stranded telomeric (CCCTAA)n DNA circles (C-circles) appears to correlate with ALT activity
[71]. Third, the occurrence of telomere sister chromatid exchanges (T-SCE) is generally
increased in ALT cells [72, 73]. Fourth, in ALT cells promyelocytic leukemia nuclear bodies
(PML-NBs) associate with some telomeres [64, 74]. These complexes are called ALT-associated
PML-NBs (APBs) [64, 65].
Which type of telomere maintenance mechanism is active seems to depend on the origin of
the tumor. ALT is rarely found in carcinomas but frequently activated in tumors of mesen‐
chymal and neuroepithelial origin like osteosarcomas, liposarcomas or astrocytomas [75, 76].
Therefore, at least two mechanisms of telomere maintenance, telomerase activity and the
recombination-based ALT, may be more or less prevalent in different tissues undergoing
tumour formation, leading to the aforementioned features [77, 78]. The activation of such a
mechanisms causes the alteration of telomere length that is reflected by a hypervariability of
telomere length already observed in different human solid tumors [79-81], and also in brain
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tumors [82-87]. Hence, analysis of telomere length variations and of length modulation
mechanisms may provide promising information for their potential role as prognostic marker
or therapeutic target in cancer.
3. Telomere in aging and disease
Aging can be defined as the progressive decline of tissue function that eventually results in
mortality [88]. Aging is a natural occurring process and not a disease state. While aging is
inevitable for all humans, the speed of age-related functional deterioration varies considerably
amongst individuals. Why some individuals reach frailty earlier than others is not understood
and genetic factors as well as environmental exposures are believed to modulate the senescence
process. Currently, aging is viewed as a generalized process occurring in all organ systems in
a parallel fashion [88]. However, recent studies point towards a much higher degree of
complexity in the aging process and accumulating data support the notion that diseases
incurred during life may accelerate the aging of certain organ systems [89].
Telomeres shorten as we age. Consequently, telomere length has been postulated as a marker
of “genetic age” (mitotic clock), as a fundamental explanation for the aging process, and has
been marketed as a simple predictor of longevity. Telomere length indeed reflects the cell’s
past proliferative history and future propensity to apoptosis, senescence, and transformation.
However, cellular aging is not equivalent to organ or organismal aging. Studies in humans
have attempted to relate short telomeres to longevity. In a provocative initial publication from
the University of Utah, individuals around 60 years of age who had the longest telomeres lived
longer than did subjects with the shortest telomeres, but the most associated cause of death in
the latter group was, inexplicably, infection, and those with shorter telomeres did not have a
higher rate of cancer deaths [90]. Heart disease as the cause of death was also more common
in subjects with the shortest telomeres. Subsequent studies have produced conflicting findings.
The Cardiovascular Health Study of subjects over 65 years of age found that individuals in the
shortest quartile for telomere length were 60% more likely to die than those in the longest
quartile [91]. Causes of death related to short telomeres were infectious. Two twin studies at
older age also correlated shorter telomeres with poorer survival [92, 93]. Finally, a cohort study
that looked at participants at time zero and after 10 years found that death within 10 years was
significantly more common in those with shorter telomeres [94]. In contrast, these associations
have not been confirmed in other studies of older subjects. Njajou and collegues reported that
telomere length failed to predict survival, but correlated with years of healthy life [95]. In a
Danish study of people aged 73 to 101 years, telomeres correlated with life expectancy in simple
univariate analysis but, when corrected for age, did not predict longevity [96]. In Dutch men
with a mean age of 78 years, telomere length eroded with aging but failed to correlate with
mortality [97]. In a Finnish investigation, telomere length did not predict overall mortality [98].
Finally, in an analysis from California, short telomere length predicted death from cardiovas‐
cular disease in women but not in men, where the rate of shortening predicted mortality rather
than length itself [99]. Collectively, data on association between telomere length and aging are
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quite inhomogeneous and contradictory, whereas data on the role of telomere length in human
disease are more consistent.
Telomere dysfunction and telomere length alterations have been reported as responsible of
various human pathologies, ranging from neurodegenerative to inherited genetic diseases. In
the last decade, several studies elucidated telomere’s role in the pathophysiology of different
diseases at a molecular level. For this reason, measuring of telomeres in peripheral mononu‐
clear cells or in whole blood samples has been applied to patients with a multitude of disease
states [100].
Dyskeratosis congenital (DC), is a rare inherited bone marrow failure disease, and can be con‐
sidered the classic “telomere disease”. The inherited defect in X-linked dyskeratosis congenital
was identified in a gene named DKC1 [101]. DKC1 encodes dyskerin, a protein that binds to the
RNA component of telomerase and stabilizes the telomerase complex. Inheritance is X-linked
recessive, autosomal dominant, or autosomal recessive. In addition to the diagnostic triad of
nail dystrophy, lacey reticular pigmentation, and oral leukoplakia, patients with DC are at very
high risk of bone marrow failure (BMF), cancer, pulmonary and liver disease, and multiple oth‐
er medical problems [102, 103]. Several studies demonstrated that patients with dyskeratosis
congenita have accelerated telomere shortening and that telomere length measurement by flow
fluorescence in situ hybridization in peripheral blood lymphocytes is an important diagnostic
test for DC: in particular, age-adjusted values provide a quantitative measure of disease severi‐
ty, with shortest telomeres associated to severe variants of DC [104, 105].
Much attention has been given to individuals with atherosclerotic disease and, as a common
rule, telomeric length of peripheral mononuclear cells seems to be a strong predictor for disease
progression. In particular, leukocyte telomere length is associated with measures of subclinical
atherosclerosis [106] and with HDL cholesterol levels [107]. Moreover, cellular aging reflected
by shorter leukocyte telomere length is a predictor for advanced atherosclerosis and cardio‐
vascular disease risk [108]. Patients with myocardial infarction have shorter telomeres as
compared to controls [109], and reduced leukocyte telomere length has been linked to
increased coronary artery calcium [110] and reduction in left ventricular mass.[111] Shortened
telomeres have been observed also in white blood cells of patients affected by diabetes type I
and II,[112-114] neurodegenerative disease including dementia and Alzheimer disease
[115-119], ischemic stroke [120]. All these results suggest an important role of telomere and of
its length modulation mechanisms in the pathophysiology of several common diseases, often
age-related, encouraging new researches to improve the knowledge about telomere biology
and to translate these new informations in the clinical practice for a better patient’s manage‐
ment in terms of diagnosis, treatment and prognostic stratification.
4. Telomeres and cancer
Functional telomeres protect chromosome ends from recombination and fusion, and are
therefore essential for maintenance of chromosomal stability [3, 121, 122]. The alteration of
telomere length homeostasis affects telomere structure and leads to genomic instability by
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generating chromosome end-to-end fusion and chromosomal abnormalities [9]. It has been
demonstrated that telomeres shortening could initiate successive events, such as aberrant
fusion or recombination of the end of chromosomes, genomic instability, loss of cell growth
control, and finally cancer development [10, 11]. Cells exhibiting critical telomeres shortening
and genomic instability thus present an increased capacity of dicentric chromosomes forma‐
tion and susceptibility to oncogenic transformation [5, 12, 13].
The phenomenon of telomeres alteration during carcinogenesis and cancer progression is well
known and established at the molecular level [123-125]. Several studies demonstrated the
presence of telomere length alterations in different human solid tumors, such as prostate,
breast, colorectal, head and neck cancer [81]. These alterations are widely variable, resulting
in both telomere attrition and elongation as compared to adjacent normal tissues. In the
majority of cases, telomere length seems to be reduced in human tumors [126-131], even if it
tends to increase along with malignancy of tumors [79, 132, 133].
In particular, telomere dysfunction has been extensively studied in the most common solid
tumors. These studies demonstrated telomere length modification in different histologies as
compared to normal tissue due to the alteration of telomere length modulation mechanisms
[81]. This differences have been widely analysed in order to identify new cancer biomarkers,
to investigate the eventual correlation with patient’s prognosis and to discover new targeted
molecular therapies.
In breast cancer, multiple studies have showed that telomere shortening is associated with
increased risk and poor outcome, and can thus be used as a prognostic factor to predict the
course of disease. The first report describing the use of telomere length as a possible prognostic
marker in breast cancer was published by Odagiri and collegues [130]. In this study, telomere
length analysis was performed in a cohort of 41 patients diagnosed with breast cancer and
showed that telomere length was significantly reduced in tumor tissues (8.1 ± 0.6 kb) as
compared to that of the adjacent normal breast tissues (9.7 ± 0.5 kb) in 18 of 22 patients (p >
0.05). Subsequent studies confirmed the potential role of telomere length as clinical biomarker
in breast cancer, including Fordyce et al. [127] who reported measurements of telomere length
in 2 independent sets of breast tumors containing a total of 140 samples. This study showed
that telomere alterations include both telomere attrition and elongation. In fact, only 50% of
all tumors had telomere values in the normal range. Moreover, in this study telomere length
was associated with tumor size (p = 0.02), TNM stage (p = 0.004), 5-year overall survival (p =
0.0001) and 5-year disease-free survival (p = 0.0004) and, in particular, reduced telomere length
was associated with nodal involvement (p < 0.0001).
Recent investigations concerning prostate cancer suggest that reduced telomere length is
associated with poor clinical outcome and markers of disease progression [126, 128]. The first
reported study was performed by Donaldson and colleagues in 1999 and represented a
retrospective investigation of the relationship between clinical outcomes in patients with
organ-confined prostate adenocarcinoma and telomere length [128]. In this archival case-
controlled study, association analysis for telomere length and survival and telomere length
and biochemical recurrence indicated by PSA levels of > 2.5ng/ml, revealed that reduced
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telomere length correlated with death (p < 0.0001) and disease recurrence (p < 0.0001), even if
there was no statistical association with patients’ ages at diagnosis, nodal statuses, pathological
grades or Gleason sum scores. This finding was recently confirmed in a larger retrospective
population-based study comprising 77 men who underwent prostatectomy between 1982 and
1995 [126]. In this cohort, telomere length was a predictor of time to recurrence when adjusted
for age at diagnosis, Gleason sum score and pelvic node involvement.
Although relatively rare, researches on the role of telomeres in lung cancer showed that
telomerase expression and activity can be considered important contributors to the malignant
phenotype in lung epithelial cells, and have been proposed to be of potential prognostic value
[134]. Conversely, reports on the use of telomere length to predict lung cancer progression are
scarce. Shirotani et al. investigated the relationship between telomere length and various
characteristics of tumor cells in 46 lung cancer specimens, comprising 40 primary and 6
metastatic lesions [135]. In partial accordance with recent studies in breast and prostate cancers
[126, 127], the authors observed both elongation (2 cases) and reduction of telomere length (13
cases) in the 16 small cell carcinomas of the sample set. The 2 cases with telomere elongation
were associated with a poor prognosis. Similarly, in the adenocarcinoma samples of this study,
both telomere reduction and elongation were observed, but a clear association with patients
prognosis was not reported. Hirashima et al. evaluated the prognostic significance of telomere
length alterations in cancer and normal lung tissues obtained from 72 patients with histolog‐
ically confirmed pathological stage I-IIIA non-small cell lung cancer (NSCLC) [136]. In this
study, the 25 patients (34.7%) with alterations in telomere length, elongation or attrition, had
significantly shorter survival durations than those of the others.
The use of telomeres as prognostic factors in colorectal carcinoma has been suggested in several
studies performed by the groups led by Siewert and coworkers[132, 137] and by Iniesta and
collegues [133]. It is interesting that these studies showed an opposite relationship as compared
to studies in other cancer types [126-129, 131], with longer telomeres associated with poor
prognosis. This difference may be explained considering the different regulation of telomerase
expression in colorectal epithelial cells. Normal colorectal epithelium, in fact, has been showed
to contain cells of possible stem cell origin that are telomerase-positive and presumably
counteract telomere attrition due to physiologically high cell proliferation rates, and total cell
loss due to physiological shedding in this specialized cell compartment [138]. Consequently,
it is possible that the existing high telomerase activity may affect cells undergoing tumor
initiation and results in elongated telomeres in cells of colorectal cancer.
Studies indicating the prognostic potential of telomeres have also been reported for head and
neck cancer. Patel et al. studied telomere alterations in tumor and adjacent normal tissues in
110 patients with head and neck cancer (squamous cell carcinomas of the oral cavity, larynx
and pharynx) and 40 patients with precancerous and benign conditions (leukoplakia, submu‐
cous fibrosis, erythroplakia, hemangioma) [79]. Telomere lengths in this sample set were
significantly lower in malignant tissues as compared with the tumor adjacent normal tissues.
In addition, 2-year disease-free survival analysis showed that patients with longer telomeres
in malignant tissues had poor disease-free survival. These findings are in agreement with that
reported for colorectal carcinoma and lung [132, 133, 135, 137], and in contrast to other cancer
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histologies [126-129]. A possible explanation for these interesting discrepancies in head and
neck cancer is the fact that telomerase activity was observed in over half of the adjacent normal
tissues. As before discussed for colorectal carcinoma, altered regulation of telomerase expres‐
sion in cells undergoing transformation may explain the elongated telomeres in the tumors.
Collectively, these findings suggest that hypervariability of telomere length in various human
solid tumors probably reflects the differential regulation of telomerase expression in cancer
cells and depends on the different stages of carcinogenesis and tumor progression. Therefore,
analysis of telomere length may have a clinical relevance as a prognostic marker in human
solid tumors, whereas analysis of the mechanisms of length modulation, such as telomerase
and ALT, can suggest new molecular target for advanced therapeutic strategies.
5. Telomeres and brain tumors
Brain tumors research is being performed worldwide at a remarkable pace, with some of the
more recent promising studies focused on identification of aberrant genetic events and
signalling pathways, tumor stem cell identification and characterization, modulation of tumor
immunological responses, combination therapies, and understanding of the rare long-term
survivors. Identification of additional indicators will enable better patients’ stratification and
individualization of treatment is needed to more accurately determine patient’s prognosis and
to identify novel therapeutic approaches that can optimize patient’s outcome. A growing body
of knowledge suggests a potential role of telomere length measurement in different tumors.
Nevertheless, even if its clinical use is not completely established, a number of studies
demonstrated that it can be helpful to patients stratification, to provide useful information
about patient’s prognosis and, in some case, to suggest new therapeutic strategies in cancer.
Although not entirely consistent in the type of telomere alteration, i.e., attrition vs. elongation,
and unclear on the underlying mechanisms, multiple studies have showed that telomere
dysfunctions are associated with parameters of clinical outcome in patients with brain tumors.
A possible explanation for these interesting discrepancies in brain tumors is the fact that
different expression and/or altered regulation of telomerase expression in tumor cells may
reflects the underlying biology of telomere maintenance and its dysfunction over time. In
telomerase positive tumor cells, telomere length is balanced by telomere shortening due to cell
division and telomere elongation by telomerase. Therefore, telomere length is maintained by
telomerase activity that can be influenced in different ways and by various factors. This
mechanism keeps tumour cells proliferating and growing by the stabilization of their telomeres
which is essential to maintain the unlimited dividing potential and to escape from ‘crisis’ [49,
123, 139]. As well as in almost all malignant tumors, World Health Organization (WHO) high
grade brain tumors are associated to higher telomerase activity than benign tumors, such as
schwannomas, meningiomas [140] or normal brain tissue [141]. Increased telomerase expres‐
sion has been also associated with higher proliferative index, tumor grading, age, vascular and
endothelial proliferation [142], poor outcome [83, 143, 144], and it increases with malignancy
from low-grade to high-grade brain tumors [83, 145].
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Therefore, understanding the context and mechanisms by which telomeres length contribute
to cancer development is the next logical research step and may represent an interesting
research field in order to elucidate brain tumors biology. Moving toward the study of molec‐
ular mechanisms controlling telomere length, included telomerase and ALT, will not only
provide insight into the complex etiology of brain tumors but also promises to provide novel
targets for cancer therapy.
In these settings, several studies have been performed to analyze telomere biology in brain
tumors, with the aim to better understand the patophysiology of these tumors for improving
prognosis of patients affected by such terrible neoplasms.
5.1. Astrocytic gliomas
Astrocytic tumors represent about the 23% of primary brain and CNS tumours and, in
particular, astrocytomas and glioblastomas (GBMs) account for 76% of all gliomas. The
incidence of such tumours tends to increase with age, although some histological variants are
more frequent in specific age ranges. For example, pilocytic astrocytomas affect exclusively
childhood, being the most common brain tumor between 5 and 14 years old. Conversely, the
incidence of glioblastomas increases with age, with the highest rates in the 75 to 84 years old.
The prognosis can be different according to histology. For low grade astrocytomas (grade I
and II), prognosis is usually good and a gross total surgical excision alone represents a
sufficient therapeutic strategy. Conversely, for high grade astrocytomas (i.e. glioblastomas
WHO IV), although a multimodal therapeutic strategy consisting of radical surgical removal,
chemotherapy and radiotherapy, prognosis remains poor. For example, five–year survival
rates are 94% for pilocytic astrocytomas but are less than 5% for glioblastomas. Survival
generally decreases with older age at diagnosis. Children and young adults have better
survival for most histologies [146].
Several studies focused on astrocytomas showed an association between telomerase activity
and reduced telomeres length in high grade tumors. Liu et al. analyzed telomere length in a
series of astrocytic tumors. Telomere length measurement was performed using a telomere
specific restriction enzyme and Southern blot analysis. The authors observed a progressive
shortening of the telomere restriction fragments (TRFs) in astrocytomas from WHO grade I to
IV as compared to TRFs of normal brain tissue, with no significant differences between primary
and recurrent GBMs [87]. These findings support the hypothesis that telomere shortening is
one of the important genetic events during transformation of astrocytomas and progression
to higher grades.
Subsequent studies were focused on the analysis of the relationship between telomere length
and telomerase activity, suggesting new interesting hypothesis about telomere maintenance
mechanisms during the neoplastic transformation and progression of astrocytic tumors. In
1997, Morii and colleagues, analysed telomere length and telomerase activity in a series of 20
gliomas (WHO grade I to IV), including 1 pilocytic astrocytomas, 7 oligoastrocytomas, 1
anaplastic astrocytoma (AA) and 11 GBMs. In their series, telomerase-positive samples had a
mean TRF length of <10 kb, whereas telomerase-negative samples all had long heterogeneous
TRFs which exhibited an increased signal peak from 10 to 20 kb. The authors concluded that
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telomerase-negative gliomas had longer TRFs compared with telomerase positive ones,
suggesting that, in addition to the telomerase-dependent mechanism, an alternative telomer‐
ase-independent mechanism (ALT) for telomere maintenance may be present in human
gliomas [86]. Hiraga et al, in 1998, performed the most complete analysis of telomere length
in human brain tumors, comparing TRFs length and telomerase activity in 160 neuroepithelial
and non-neuroepithelial brain tumors. Among grade I-IV astrocytomas, the authors compared
telomere length between telomerase-positive and telomerase-negative samples vs normal
brain tissue (NBT). TRFs were shorter in tumors with telomerase activity than telomerase-
negative samples and NBT samples. Specifically, the detection rates of telomerase activity were
widely different for different histopathological entities. Telomerase activity was detected in
none of pilocytic astrocytomas, in 20.0% (3 of 15) of grade II astrocytomas, 40% (6 of 15) of
anaplastic astrocytomas and 72.3% (34 of 47) of glioblastomas, suggesting that telomerase
activity tend to increase with the malignancy of astrocytic tumors. In particular, all pilocytic
astrocytomas (3 of 3) were telomerase negative and showed longer TRFs as compared to
normal brain tissue. TRFs in grade II astrocytomas and anaplastic astrocytomas with telomer‐
ase activity were shorter as compared to the same tumors without telomerase activity. Lastly,
80% of the progression GBMs exhibited reduced mean TRF length (7.747 kb) compared with
NBT and origin tumors, and telomerase was reactivated in 100% (10 of 10) of cases. In
summary, the mean TRF length of tumors with telomerase activity was significantly shorter
than that of tumors with undetectable telomerase activity for each tumor entity [139].
These results suggest that telomerase activity strongly correlates with malignancy and
potential progression of the astrocytic tumors, being often associated with reduced telomere
length.
These findings were confirmed by Le et collegues, in 1998 [83]. The authors performed an
analysis of telomere length and telomerase activity in a series of 69 grade I-IV gliomas. From
the analysis of all series, the authors concluded that telomerase activity is present in most
glioma samples (72%), but that the frequency of such activity increases with malignancy, being
higher in high grade gliomas (HGGs) than in low grade gliomas (LGGs), and is often associated
with telomeres shortening. This can be explained with the relative low replicative rate of LGG
tumor cells. When the proliferative activity increases, such as during the progression to HGGs,
the increased mitotic activity causes a progressive telomeres shortening. In this condition, the
activation of telomerase activity represents the only way to escape from cell crisis and
apoptosis. This can explain the presence of high telomerase activity and reduced TRFs only in
a small percentage of LGGs that probably presents a more aggressive behavior than the
telomerase negative LGGs with normal or elongated telomeres. This demonstrates an increas‐
ing telomerase activity with the more malignancy of gliomas samples, underlying the role of
telomerase and TRFs length as marker of malignancy.
Similar findings were found by Maes and collegues in 2007 [145]. They conducted a study
focusing on the relationship between telomerase activity and telomere length in a series of 53
intracranial tumors, including 2 low grade astrocytomas, 1 anaplastic astrocytomas, and 11
GBMs. Again, in this study the authors demonstrated that telomere length was reduced in
high-grade tumours, whereas it was compatible or elongated as compared to normal brain
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tissues in low-grade astrocytomas, suggesting that telomerase activity with shortened
telomeres correlates with the aggressive growth of high-grade gliomas.
Harada and colleagues [147] analyzed possible differences of telomerase activity and telomere
length among primary and secondary GBMs. Summarizing their findings, TRFs were always
shorter than NBT samples, but not statistically significant differences between primary and
secondary GBMs were found. Interestingly, although the latter presented significantly higher
levels of telomerase activity and hTERT expression than the former, telomere length was
anyway shorter than normal brain tissue. The authors explained this apparent discrepancy
suggesting that telomerase activation occurs late in carcinogenesis, when the high replication
rate of tumor cells already caused telomeres shortening. At this point, activation of telomerase
represents the principal mechanism to escape from apoptosis and cell death. Conversely, in
primary GBMs, shorter telomere length can be explained by a reduced telomerase activity that
might have less influence on carcinogenesis and, hence, other unknown factors might facilitate
their cellular immortality.
Although the vast majority of the researches have been performed focusing their attention to
telomere length and telomerase expression in astrocytic gliomas, recently several studies
showed an increasing interest also to the analysis of the relation between ALT mechanism,
telomere length and patients prognosis.
The presence of elongated telomeres and of an alternative mechanism of telomere length
maintenance (ALT) was demonstrated to be associated to a better prognosis in patients affected
by GBMs by Hakin-Smith et al. in 2003 [148]. Their work represents the first report describing
the relationship among ALT pattern, telomere length, and prognosis in human GBMs. In this
study, the authors analyzed telomerase activity and telomere lengths in 77 GBM patients. ALT
phenotype patients had a median survival of 542 days compared with 247 days in those
without the ALT phenotype. Moreover, ALT phenotype was associated with elongated
telomeres, benign biology and better prognosis. Therefore, the presence of ALT could be a
positive prognostic marker in glioblastoma multiforme.
The first study that analyzed the ALT prevalence among different grades of astrocytic tumors
was performed by Henson and coworkers in 2005. In their study, the authors analyzed the
prevalence of ALT phenotype and telomerase activity in a series of 40 astrocytomas, composed
by 7 WHO grade II-III astrocytomas and 33 GBMs. This study showed for the first time that
the prevalence of ALT associated to elongated telomeres is significantly higher in grade II to
III astrocytomas as compared to GBMs.
On the basis of Henson’s results, in 2010 Slatter and collegues conducted a study focusing on
the analysis of ALT prevalence in a series of 48 astrocytic tumors from grade I to IV. In
agreement with previous studies by Hakin-Smith and Henson [148, 149], ALT phenotype was
more frequent in low grade astrocityc tumors, whereas telomerase activity was prevalent in
the higher grades.
Collectively, these studies demonstrated that telomerase activity correlates with malignancy of
astrocytic tumors, being higher with the increasing WHO grading [83, 86, 87, 139, 145, 147, 150].
Therefore, telomerase activity and reduced telomeres should be considered a potential bio‐
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marker of aggressive behaviour of these neoplasms. Conversely, low grade astrocytomas are
usually telomerase-negative and have compatible or elongated telomeres as compared to nor‐
mal brain tissue [83, 86, 139, 145, 149]. In these tumors, the only telomere length maintenance
mechanism is represented by ALT [149, 150]. Henson et al [149] and Slatter and collegues [150]
documented that ALT phenotype is associated to elongated telomeres and it is more frequent in
low grade astrocityc tumors as compared to GBMs. Moreover, Hakin-Smith and collegues [148]
demonstrated that, despite the ALT phenotype associated to elongated telomeres is rarely
documented in GBMs, when present it is associated to a longer survival, suggesting its possible
role as a positive prognostic markers in GBMs. These findings can be explained considering the
biological role of telomeres. In normal tissues as in neoplastic cells, telomeres undergo progres‐
sive shortening during each cell replication. When telomeres are critically shortened, the cell
cannot preserve anymore its own chromosomic ends and goes toward cell crisis and subse‐
quent apoptosis. Therefore, telomeres represent the biologic clock of cells and constitute one of
the most important structure that can preserve cells from senescence. This is the reason why tu‐
mor cells need a robust telomere maintenance mechanism to allow an high replicative activity,
escaping from cell death. It is well known that high grade brain tumors are malignant neo‐
plasms with an high replicative activity. Consequently, they need a mechanism of telomere
maintenance that allows cell division avoiding excessive telomere shortening that can deter‐
mine cell death. Telomerase seems to accomplish this role with success, especially in high grade
tumors. This can be the explanation of the higher telomerase activity found in brain tumors with
the increasing of WHO grading. Hence, the highest levels of telomerase expression are found in
GBMs. Conversely, low grade astrocytic tumor have a slow replication rate and thus they does
not need telomerase. According to the aforementioned studies, in these tumors the slow grow‐
ing rate is accompanied by a sluggish cell division rate. This can be the reason why the most part
of the studies in the literature documents elongated telomeres in low grade tumors. In these ne‐
oplasms, the main telomere length maintenance mechanism is represented by ALT. Being spe‐
cific of benign or slightly aggressive tumors, ALT and elongated telomere are associated to a
better survival [149, 150] even if these features are found in a low percentage of high grade brain
tumors, such as GBMs [148]. When low grade tumors progress to higher grade, the increasing
replicative activity causes a progressive telomere shortening. In this condition, the only way to
escape from cell death is the activation of telomerase activity. This is typically observed in pro‐
gression GBMs [139].
In summary, high telomerase activity and reduced telomere seem to be features of high grade
astrocytic tumors, whereas elongated telomeres and ALT phenotype are specific of low grade
ones and, therefore, correlates with a better prognosis.
Different studies have also been performed to analyze the role of the Shelterin proteins in the
pathophysiology of several neoplasms, including brain tumors. Telomere-specific DNA-
binding proteins, such as TRF1, have been put forward as additional candidates for the role
of molecules modifying telomerase activity, and they have been suggested to play key roles
in the maintenance of telomere function [41, 55, 56]. It has been demonstrated that overex‐
pression of TRF1 inhibits telomere elongation in telomerase-positive cells [151], resulting in
gradual and progressive telomeres shortening to the “mortality stages,” the proliferative
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barriers that lead to a non-dividing state and cell death [24, 151, 152]. The mutation or deletion
of TRF1 can result in telomere elongation and extend cell survival [151]. Overexpression of a
dominant negative TRF1, which removes endogenous TRF1 from telomeres, results in
telomere lengthening in telomerase-positive cells [151] [153]. Therefore, the expression of TRF1
is considered a physiological homeostatic mechanism that controls the proliferative potential
of normal cells by inhibiting the activity of telomerase [151].
It has been demonstrated that TRF1 is expressed in astroglial brain tumors of different grades,
whereas it is not expressed in normal brain tissue. Such expression decreases from low-grade
through high grade astrocytomas [123]. This finding may suggest that the loss of TRF1
expression capability, being the result of down- regulation of TRF1 expression in malignant
gliomas cells, may play a role in the cell immortalization of astroglial brain tumors.
Furthermore, according to the role of telomerase in the elongation of telomeres in high grade
astrocytic tumors, several studies suggested its possible role as molecular target for new
therapeutic strategies. Marian et al demonstrated that the telomerase antagonist Imetelstat
efficiently targets glioblastoma tumor-initiating cells leading to a decreased proliferation and
tumor growth [154]. Gurung and collegues showed that Thymoquinone induces telomere
attrition, DNA damage, cell cycle arrest and apoptosis in the glioblastoma cells by inhibiting
the activity of telomerase [155]. Lin et al documented that Butylidenephthalide (BP) inhibits
proliferation and induces senescence in human glioblastomas by downregulating hTERT
expression and consequently telomerase activity [156]. From this perspective, telomerase
represent a promising target for new specific therapeutic approaches for the personalized
treatment of telomerase-positive high grade astrocytic tumors.
5.2. Ependymomas, oligodendrogliomas and mixed tumors
Ependymomas are tumors that arise from ependymal cells lining the cerebral ventricles and
the central canal of the spinal cord. They represent the 5-6% of intracranial gliomas ( 69% occur
in children) and 60% of spinal cord gliomas ( 96% occur in adult) [157]. In pediatrics they are
usually intracranial (the most common localization is the posterior fossa), whereas in adults
they tend to be spinal. The treatment of choice is the radical surgical excission followed by
radiotherapy (XRT), whereas the role of chemotherapy is very limited. The operative mortality
is 5-8%, the 5 year survival is 20-30% in pediatrics and 80% in adults [158, 159].
Data on telomeric alterations in adult and pediatric intracranial ependymomas are slightly
inhomogeneous. In 2008 Ridely et al. performed an analysis of telomere length in a series of
21 primary and recurrent pediatric intracranial ependimomas from 7 patients (6 primary
tumors and 15 recurrences) [84]. Telomerase activity was detected in 19 tumors (86%), and
particularly it was evident in 11 of 14 primary tumors and in all recurrent tumors. Mean
telomere length ranged from 7.3 to 16.7 kb, with telomere maintenance observed in five of
seven patients (71%). Of these five cases, four showed telomere lengthening and one had
compatible TRFs in relapsed tumors as compared to the primary tumor. Conversely, telomere
shortening occurred in two of seven recurrent cases (29%).
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The authors concluded that variable TRFs length and evidence for telomerase-mediated
telomere maintenance were present in the majority of pediatric ependymoma recurrent cases
(71%), whereas TRFs shortening was evident in a minority (29%). These results implicate
telomerasemediated telomere maintenance as a key mechanism facilitating tumor progression
in pediatric ependymoma.
This was demonstrated by the fact that all recurrent tumors analyzed were telomerase positive,
although telomere length was reduced only in small percentage of cases.
In the same year, Tabori et al evaluated TRFs length in a series of 26 pediatric intracranial
ependymomas (grade II and III), analyzing an eventual correlation with patients’ prognosis
[85]. Telomerase activity was detected in 73% of tumor samples but TRFs length was widely
variable (mean 6.5 kb,range 3.6–9.1 kb). Based on these findings, although ependymomas rely
predominantly on telomerase activity to maintain their telomere length, the authors concluded
that there was no correlation between telomere length and telomerase expression or survival.
Although it seems to emerge that the majority of intracranial ependymomas (especially in
children) shows telomerase activity, telomere length appears to be widely variable. Therefore,
there is a lack of a firm correlation of telomere length with telomerase expression that do not
allows to get definitive conclusions about their possible role as prognostic marker in these
neoplasms. It is more probable that these findings reflect an high molecular variability of
intracranial ependymomas.
Oligodendrogliomas arise from oligodendroglia cells. They represent 25-33% of glial tumors
[160, 161] and have an incidence peak at 40 years, with a smaller earlier peak in childhood
between 6-12 years [162]. They show a slight preference for male, with a male-female ratio of
3:2. In 90% of cases they are supratentorial. Surgery is the treatment of choice; chemotherapy
is recommended, whereas XRT is suggested only for anaplastic variants [163]. The median
survival for surgically treated lesions is 35 months [164], although the ten-year survival is
about 10-30% [165]. According to Nurnberg [82] and Hiraga [139], oligodendrogliomas seem
to have compatible or longer telomeres than normal brain tissues and detectable telomerase
activity. The lack of reduced telomeres in telomerase positive tumor samples can be consid‐
ered a marker of the less aggressive behavior of such tumors.
Different results have been reported for oligoastrocytomas, that show shorter telomeres than
normal brain tissue associated to high telomerase activity [86]. This pattern is more frequent
in the anaplastic variant, confirming the role of telomerase activity associated to reduced te‐
lomeres as markers of aggressive behavior in these neoplasms as in astrocytic gliomas[139].
5.3. Meningiomas
Meningiomas are extra-axial, usually benign tumors with a slow growing rate that arise from
arachnoid cells. They account for 34% of all primary brain and CNS tumors [146]. The incidence
peak is at 45 years with a male-female ratio of 1:2,2. About 1.5% occur in childhood and
adolescence between 10-20-yeras age [166]. Surgery is the treatment of choice for symptomatic
meningiomas and the five-year survival is 91.3% [167].
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Benign mengiomas (WHO grade I) show a variable telomere length [82, 139, 168], sometimes
slightly shorter than normal meningeal tissue [145], whereas atypical and anaplastic menin‐
giomas show telomerase activity associated with a significant telomere length shortening [169].
This can be explained considering that the slow growth of benign meningiomas and the
absence of telomerase activity cause an equally slow shortening of telomeres, whereas the
higher replicative capacity of atypical and especially of malignant meningiomas determines a
more evident reduction of telomere length. In these settings, the activation of telomerase
activity can give to the cell the capacity to escape from senescence and, consequently, an high
proliferative strength. Therefore detectable telomerase activity and shortened telomere length
suggest that the tumor contains a cell population with the capacity for unlimited proliferation.
These results indicate that telomere shortening together with telomerase activity may be a
critical step in pathogenesis of atypical and malignant meningiomas and may correlate with
their malignant behavior. Indeed, as previously discussed for astrocytic tumors, the association
of telomerase activity with reduced telomeres length may be considered a marker of an
aggressive behavior also in meingiomas, being more frequent in atypical and malignant
meningiomas.
5.4. Schwannomas
Schwannomas are benign, usually encapsulated, peripheral nerve sheath tumor composed of
neoplastic Schwann cells that can have an intracranial or spinal localization. They account for
about 8-10% of intracranial and 25-30% of spinal tumors. The peak of incidence is between the
4th and 6th decades [146]. The vast majority of intracranial Schwannomas develops from
vestibular nerve. Tumors of trigeminal or facial nerve are far less common. Management
includes many options: surgery, wait and see strategy for little or no growth tumors, radiation
therapy alone or in conjunction with surgery, chemotherapy, radiosurgery [170].
Schwannomas usually show reduced telomeres, benign pathological features, low prolifera‐
tive indices and a lack of telomerase activity [169, 171]. These peculiarities allows such tumors
to have a benign clinical course. Conversely, rarely they can assume an aggressive behaviour
that is characterized by malignant pathological features and high replicative potential that are
usually associated to elongated telomeres. This can be explained considering that long
telomeres allow tumor cells to maintain an high proliferative capacity without the need of
telomerase activity. When the length of the telomere is long enough for proliferation, the
telomerase activity subsides.
For these reasons, telomeres elongation, even in absence of telomerase activity, can be
considered a marker of aggressive clinicopathological behaviour in schwannomas [169, 171].
5.5. Primitive Neuroectodermal Tumors (PNETS)
Primary neuroectodermal tumors (PNETs), also called embryonal tumors, represent 1 % of all
primary central nervous system (CNS) tumors. They are frequent especially in children, repre‐
senting the most frequent brain and CNS tumor in the range between 0 and 4 years old [146].
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They are highly malignant lesions and can disseminate via CSF spontaneously or iatrogenically
[172]. Extraneural metastases can also occur. Radical surgical excision is the treatment of
choice. XRT is indicated following surgical removal, but it should be avoided at all if possible
before 3 years of age to avoid intellectual impairment and growth retardation. Overall survival
rate for PNETs is substantially poor with an expected 3 year progression free survival of
approximately 50% for localized supratentorial PNETs [173].
PNETs usually show telomerase activity even if there is not a clear association with telomere
length. Despite Hiraga [139] and Rahman [174] reported reduced telomeres in the most part
of tumor samples, data from Didiano [175] document a wide variability of telomeres length.
Interestingly, Rahman reported shorter telomere length in PNETs cells than GBMs, suggesting
an higher replicative activity in the former as compared to the latter. These results underline
and explain the aggressive behaviour of neuroectodermal tumors. The same author, reported
a minority of cases with elongated telomeres and undetectable telomerase activity, suggesting
ALT as alternative mechanism of telomere maintenance in these tumors [174].
In summary, telomerase activity can be considered a marker of PNETs and can explain the
malignancy of these tumors, although there is not an evident correlation with telomere length.
Moreover, in a little percentage of cases without telomerase activity, the aggressive behaviour
of PNETs is due to ALT and is associated to elongated telomeres, that allow tumour cells to
actively replicate [175].
5.6. Pituitary adenomas
Pituitary adenomas are usually benign tumors that arise from anterior pituitary cells (adenohy‐
pophysis). They represent about 13% of primary brain and CNS tumors with an incidence peak
on 3th and 4th decades of life [146]. Treatment of pituitary adenomas include medical treatment
(dopamine agonists, somatostatin, etc), surgery (transcranial or transsphenoidal approach) or
XRT (in case of recurrence that cannot be surgically removed or treated medically).
Their usually benign behaviour can be explained with the lack of telomerase activity, although
telomere length is slightly reduced as compared to normal brain tissue [139]. Sometimes they
can recur or, rarely, they can progress to pituitary adenocarcinomas. As demonstrated by
Harada and colleagues, during progression to carcinoma, the replicative activity of tumor cells
causes a progressive shortening of telomeres and the reactivation of telomerase [176]. There‐
fore, also in pituitary adenomas, telomerase activity and reduced telomere length can be
considered marker of aggressive behaviour and can be used to predict the progression to
carcinomas.
5.7. Primary Central Nervous System Lymphomas (PCNSLs)
Primary central nervous system lymphomas (PCNSL) also known as primary brain lympho‐
mas are a primary intracranial tumors appearing mostly in patients with severe immunosop‐
pression (typically patients with AIDS). They represent the 0.5-1.2% of intracranial tumours
and less than 1 % of extranodal non-Hodgkin lymphomas (NHL), although in the last years
there was a progressive increase of incidence also in immunocompetent patients. They affect
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all age groups, but are most commonly diagnosed in people who are over 50 years of age.
Histologically they are a form of extranodal, high-grade non-Hodgkin lymphoma. Most
PCNSLs (about 90%) are diffuse large B-cell lymphomas (DLBCLs); the remaining 10% are
poorly characterized low-grade lymphomas, Burkitt lymphomas, and T-cell lymphomas [177].
PCNSLs originate inside the CNS and typically remain confined, rarely spreading outside the
nervous system. Although the origin cells are lymphocytes, PCNSLs can be assimilated to brain
tumors for their intracranial localization and relationship with brain parenchyma and brain
blood barrier that gives PCNSLs the same therapeutic challenges (i.e. in terms of drug delivery
through the blood brain barrier) of the other brain tumors.
Data from the literature demonstrate that in PCNSLs have variable telomere length, usually
reduced as compared with normal brain tissue, and show high telomerase activity [139, 178].
Harada et al demonstrated a statistically significant correlation between telomerase activity
and the survival period of patients with PCNSL. In particular, patients with high telomerase
activity had poor prognosis and short survival, regardless of telomere length [178].
These findings suggest that telomerase activity represents a common features in PCNSLs and
can be considered by itself a marker for predicting a poor prognosis, regardless of telomeres
length, the age at onset and the KPS score before the initial treatment. Nevertheless, telomeres
are usually shortened in these tumors and this can explain the aggressive behavior of such
tumors, even if the association with patients’ survival has not been demonstrated.
5.8. Other intracranial tumors
Only few studies have been performed focusing on the analysis of telomere length and
telomerase activity among less common non-neuroepithelial tumors, such as hemangioblas‐
tomas, hemangioperycitomas and germ cell tumors.
Hemangioblastomas are benign tumors that usually show normal telomere length and
undetectable telomerase activity. Nevertheless, the rare cases of hemangioblastomas with
aggressive behavior show shorter telomeres than normal brain tumors and are telomerase-
positive [139].
Conversely, malignant non-neuroepithelial tumors such as hemangioperycitomas and germ
cell tumors, usually show high telomerase activity associated to an important shortening of
telomere length [139].
This suggest that, also for these rare non-neuroepithelial brain tumors, telomerase activity
associated to reduced telomere length can be considered a marker of malignancy.
6. Conclusions
There is a desperate need for developing innovative diagnostic tools and therapies for brain
tumors.
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According to their role in the regulation of cell replication and senescence, telomeres and
telomeric proteins represent a new interesting research field to better understand the altera‐
tions responsible of carcinogenesis and malignant progression of human brain tumors. In these
settings, elucidation of telomeres biology represents the new frontier of cancer research.
Although a lot of studies have already been focused on this promising field, further studies
should be performed to better understand the pathways involved in the telomeres length
maintenance and, consequently, in the process of carcinogenesis and malignant progression
of human brain tumors, in order to discover new diagnostic/prognostic tools or new thera‐
peutic strategies for improving prognosis of patients affected by these terrible neoplasms.
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